Insider Purchases: Inside the Buy
Tag: Biotech Picks
CORT Stock 2026: FDA Rejection, Insider Buying… and a Brewing Short Squeeze?
Corcept Therapeutics just got hit with an FDA rejection—but insiders are buying millions and short interest is surging. With a profitable base business and major 2026 catalysts ahead, CORT may be one of the most explosive “binary bets” in biotech today.
Update on High-Risk, High-Reward Intellia Therapeutics: Another Insider Buys — Should You?
NTLA is the kind of stock that tests both your thesis and your pulse. Short interest sits around 36%, the FDA put a key trial on hold, and yet directors just bought ~$2.4M in shares. Here’s the fun-but-serious update on the squeeze setup, the catalysts, and the risks.
Avantor (AVTR): Insiders Loading Up, CEO Grabbing Shares by the Beaker, and a $500M Buyback — Time to Mix, Shake, or Invest?
Insiders didn’t get the memo to stop buying AVTR — they doubled down. With a fresh CEO, a big new insider buy, and a $500M repurchase program, Avantor’s “boring but essential” lab empire might be setting up a comeback… if the experiment doesn’t explode first. 🧪📉➡️📈